The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jan 18, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating whether patients with normotensive pheochromocytoma (a type of tumor) can safely skip a certain pre-surgery medication called alpha-adrenergic blockade. Traditionally, this medication is given to help manage blood pressure before surgery, but it may not be necessary for everyone. The study aims to see if omitting this medication leads to similar safety and outcomes during surgery compared to those who do take it.

To participate in this trial, individuals need to be between 19 and 70 years old and scheduled for surgery to remove a single adrenal tumor. They should not have high blood pressure or other serious heart conditions. Participants will be divided into two groups: one will take the medication for a few weeks before surgery, while the other will not. Throughout the trial, researchers will monitor blood pressure and overall stability to determine the best approach for managing surgery in these patients. This study is currently recruiting participants, and it is important for patients to discuss their eligibility with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 19 to 70 years old
• • Patients who consented to the study and obtained consent for the study
• • Patients undergoing unilateral total adrenalectomy due to normotensive pheochromocytoma/paraganglioma with less than five times of upper limits of serum metanephrine
• Exclusion Criteria:
• • Patients under 18 or over 70 years old
• • Pregnant women
• • Patients with bilateral pheochromocytoma
• • Patients suspected of malignant pheochromocytoma/paraganglioma or distant metastasis
• • Patients requiring preoperative intensive care unit due to severe hemodynamic instability
• • Patients with hypertension (the blood pressure measured more than two times is constantly greater than 140/90 mmHg) or already taking a antihypertensive medication
• • Patients with a history of coronary artery disease
• • Patients with a history of arrhythmia (atrial fibrillation, Paroxysmal supraventricular tachycardia)
• • Patients with a history of cerebrovascular disease (cerebral aneurysm, cerebral infarction, cerebral hemorrhage)
• • Patients judged unsuitable by the person in charge of the clinical trial